<i>Trypanosoma cruzi</i> infection in North America and Spain: evidence in support of transfusion transmission (CME)

Benjamin, Richard J.; Stramer, Susan L.; Leiby, David A.; Dodd, Roger Y.; Fearon, Margaret; Castro, Emma

doi:10.1111/j.1537-2995.2011.03554.x

Cited by 73 publications

(81 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The three confirmed positive cases from 6,978 donors (1:2,326) which were identified in Switzerland lies within the same range but is too low to be statistically significant. Transfusion-transmitted CD has been often reported, and it has been documented that several different blood components can be involved [3,4,12]. The infective capacity of each type of labile blood component varies from 10 to 25%.…”

Section: Discussionmentioning

confidence: 99%

“…The infective capacity of each type of labile blood component varies from 10 to 25%. PCs pose a greater risk than RBC concentrates, frozen plasma or cryoprecipitated products [4,47,48,49,50,51,52,53,54,55]. From the 3 confirmed positive cases from Switzerland, 1 donor was a first-time donor, whereas the 2 others were repeat donors.…”

Section: Discussionmentioning

confidence: 99%

“…For many years CD was restricted geographically to Latin America but due to the increased migratory flow of millions of individuals during recent decades the traditional epidemiological pattern of CD has dramatically changed. Congenital as well as transfusion-related CD cases were reported in many European countries where effective control measures and preparedness plans were not yet established [3,4]. A recent comprehensive estimation of affected European populations reported that between 14,000 and 180,000 individuals are infected with T. cruzi [5].…”

Section: Introductionmentioning

confidence: 99%

“…A chronic asymptomatic carrier state in conjunction with an asymptomatic or non-specific clinical infection course in recipients of T. cruzi -infected blood results in transfusion-transmissioncases being undetected and thus unreported. Transfusion-based T. cruzi infections are already a major route of transmission in many non-endemic countries, with several cases reported recently in USA, Canada, Spain and Mexico [3,4,12]. It is estimated that on average 20% (range 0- 40%) of the transfusion recipients of parasitaemic blood became infected [13,14,15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland

Niederhauser

Gottschalk

Tinguely

2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Population migrations and overseas recreational travel to regions at risk for tropical diseases are increasing. A major challenge in non-endemic countries is to decrease the number of blood donor deferrals due those tropical disease pathogens, without compromising the high level of blood safety. The protozoans Trypanosoma cruzi and Plasmodium spp., the causative organisms of Chagas disease (CD) and malaria are becoming a major focus in the blood transfusion community. Methods: National guidelines of the Blood Transfusion Service of the Swiss Red Cross propose an algorithm for dealing with these pathogens, including a mandatory selective serological testing of donors at risk. Results: 6,978 donors at risk for CD were tested. Three of them were confirmed anti-T. cruzi-positive, and in one case a transfusion-transmitted infection was highly possible. The specificity of the assay was 99.94%. For malaria 12,887 donors were at risk and 178 were confirmed positive. The specificity of the assays was 92.8%. Conclusion: CD and malaria in non-endemic countries may represent a certain risk for blood transfusion. Switzerland chose a selective testing approach. The specificity of the assays is a crucial topic for this approach because it ensures a minimal loss of false-reactive donors and helps towards an easier counselling of implicated donors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland

Niederhauser

Gottschalk

Tinguely

2016

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Disease-affected individuals in North America and Europe belong either to the immigrant community from Latin America or are affected by vertical parasite transmission from their mother [2,3,10,11,12]. Other primary transmission routes include ingestion of contaminated food [4], or transmission by contaminated organs or blood [5,6,7,8,9]. Transfusion-transmitted Chagas disease has been reported from endemic countries in Latin America [13]; in addition, it has rarely been described in non-endemic countries in North America and Europe [5,6,7,8,9,10,11].…”

Section: Introductionmentioning

confidence: 99%

A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland

Ries

Komarek

Gottschalk

et al. 2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Transfusion-transmitted Chagas disease has been reported from endemic countries in Latin America. Switzerland is a non-endemic country but high prevalence of antibodies against Trypanosoma cruzi was found among immigrants. Immigrants may participate in blood donation; therefore, risk-adapted anti-T. cruzi screening for blood donors was implemented in Switzerland in 2013. Methods: Between January 2013 and July 2015, 1 out of 1,183 at-risk donors, tested at Blood Transfusion Service Zurich, was found anti-T. cruzi IgG-positive. Results and Conclusion: Out of 54 donations given by the index donor (ID), we identified 77 blood products which were delivered to hospitals. Archived serum samples from the donations given during the prior 5 years were available for retrospective testing. All samples from ID revealed positive findings for anti-T.cruzi IgG. Donor-triggered look-back procedure identified a 70-year-old male recipient of a platelet concentrate (PC) donated by ID. The recipient succumbed of acute T. cruzi infection 2 years after transfusion of the PC.

show abstract

Platelet Transfusion Practices Among Very-Low-Birth-Weight Infants

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE Thrombocytopenia and intraventricular hemorrhage (IVH) are common among very-low-birth-weight (VLBW) infants. Survey results suggest that US neonatologists frequently administer platelet transfusions to VLBW infants with mild to moderate thrombocytopenia. OBJECTIVES To characterize platelet transfusion practices in US neonatal intensive care units (NICUs), to determine whether severity of illness influences platelet transfusion decisions, and to examine the association between platelet count (PCT) and the risk for IVH in the first 7 days of life. DESIGN, SETTING, AND PARTICIPANTS This multicenter, retrospective cohort study included 972 VLBW infants treated in 6 US NICUs, with admission dates from January 1, 2006, to December 31, 2007. Data were collected from all infants until NICU discharge or death (last day of data collected, December 4, 2008). Data were entered into the central database, cleaned, and analyzed from May 1, 2009, to February 11, 2016. INTERVENTION Platelet transfusion. MAIN OUTCOMES AND MEASURES Number of platelet transfusions and incidence of IVH. RESULTS Among the 972 VLBW infants (520 [53.5%] male; mean [SD] gestational age, 28.2 [2.9] weeks), 231 received 1002 platelet transfusions (mean [SD], 4.3 [6.0] per infant; range, 1–63 per infant). The pretransfusion PCT was at least 50 000/μL for 653 of 998 transfusions (65.4%) with this information. Two hundred eighty-one transfusions (28.0%) were given during the first 7 days of life. During that period, platelet transfusions were given on 35 of 53 days (66.0%) when the patient had a PCT less than 50 000/μL and on 203 of 436 days (46.6%) when the patient had a PCT of 50 000/μL to 99 000/μL. At least 1 marker of severe illness was present on 198 of 212 patient-days (93.4%) with thrombocytopenia (PCT, <100 000/μL) when a platelet transfusion was given compared with 113 of 190 patient-days (59.5%) with thrombocytopenia when no platelet transfusion was given. Thrombocytopenia was a risk factor for intraventricular hemorrhage during the first 7 days of life (hazard ratio, 2.17; 95% CI, 1.53–3.08; P < .001). However, no correlation was found between severity of thrombocytopenia and risk for IVH. After controlling for significant clinical factors and thrombocytopenia, platelet transfusions did not have a significant effect on the incidence of IVH (hazard ratio, 0.92; 95% CI, 0.49–1.73; P = .80). CONCLUSIONS AND RELEVANCE A large proportion of platelet transfusions were given to VLBW infants with PCT greater than 50 000/μL. Severity of illness influenced transfusion decisions. However, the severity of thrombocytopenia did not correlate with the risk for IVH, and platelet transfusions did not reduce this risk.

show abstract

Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission (CME)

Cited by 73 publications

References 29 publications

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland

A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland

Platelet Transfusion Practices Among Very-Low-Birth-Weight Infants

Contact Info

Product

Resources

About